ABSTRACT - 596395 The disclosure relates to a solid preparation comprising (i) compound selected from the group consisting of 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid and 2-ethoxy-1-[[2'-(45-dihydro-5-oxo-124-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt thereof (ii) a sugar alcohol selected from...

The invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin-II antagonist and/or at least one diuretic characterized in that nifedipine or nisoldipine are controlled (modified) in the body and the angiotensin-II antagonist and/or the diuretic is quickly released (immediate release (IR)) and to a method for production thereof to the use thereof as a medicine and to the use thereof for prophylaxis secon...

PROBLEM TO BE SOLVED: To provide a novel arteriosclerosis drug that controls infiltration of macrophage into an artery and is thereby capable of controlling thickening and fibrosis of aortic tunica media. SOLUTION: The arteriosclerosis drug includes nitroso nifedipine and a nitroso nifedipine derivative such as nitroso-nisoldipine nitroso-nimodipine nitroso-nicardipine and nitroso-nitrendipine nitroso nifedipine as active ingredients. The drug can control infiltration of macrophage into an arte...

PHARMACEUTICAL DOSAGE FORM COMPRISING NIFEDIPINE OR NISOLDIPINE AND AN ANGIOTENSIN-II ANTAGONIST AND/OR A Abstract The invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin-II antagonist and/or at least one diuretic characterized in that nifedipine or nisoldipine are controlled (modified) in the body and the angiotensin-II antagonist and/or the diuretic is quickly released (immediate release (IR)) a...

A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine anipamil barnidipine benidipine bepridil darodipine diltiazem efonidipine felodipine isradipine lacidipine lercanidipine lidoflazine manidipine mepirodipine nicardipine...